首页> 外国专利> Antibodies that specifically bind to human complement factor C2b

Antibodies that specifically bind to human complement factor C2b

机译:特异性结合人补体因子C2B的抗体

摘要

Provided are antibodies and antigen-binding fragments thereof that bind specifically to human complement factor C2 and are capable of inhibiting activation of the classical and lectin pathways of the complement system. The antibodies and antigen-binding fragment exhibit improved manufacturability, pharmacokinetics, and antigen sweeping. Also provided are pharmaceutical compositions comprising the antibodies and antigen-binding fragments, nucleic acids and vectors encoding the antibodies and antigen-binding fragments, host cells comprising the nucleic acids or vectors, and methods of making and using the antibodies and antigen-binding fragments. The antibodies and antigen-binding fragments can be used to inhibit the classical pathway of complement activation in a subject, e.g., a human. The antibodies and antigen-binding fragments can also be used to inhibit the lectin pathway of complement activation in a subject, e.g., a human.
机译:提供的是其特异性与人补体因子C2结合的抗体和抗原结合片段,并且能够抑制补体系统的经典和凝集素途径的活化。 抗体和抗原结合片段表现出改善的可制造性,药代动力学和抗原溶解。 还提供了药物组合物,其包含抗体和抗原结合片段,编码抗体和抗原结合片段的核酸和载体,包含核酸或载体的宿主细胞,以及制备和使用抗体和抗原结合片段的方法。 抗体和抗原结合片段可用于抑制受试者中的补体激活的经典途径,例如人。 抗体和抗原结合片段也可用于抑制受试者中补体活化的凝集素途径,例如人。

著录项

  • 公开/公告号US11161900B2

    专利类型

  • 公开/公告日2021-11-02

    原文格式PDF

  • 申请/专利权人 ARGENX BVBA;

    申请/专利号US201916714264

  • 发明设计人 CHRISTOPHE BLANCHETOT;HANS DE HAARD;

    申请日2019-12-13

  • 分类号C07K16/18;A61K39/395;A61K39;

  • 国家 US

  • 入库时间 2022-08-24 22:02:17

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号